Lucid Diagnostics Stock Performance
| LUCD Stock | USD 0.77 0.02 2.37% |
The company secures a Beta (Market Risk) of 0.31, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, Lucid Diagnostics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Lucid Diagnostics is expected to be smaller as well. At this point, Lucid Diagnostics has a negative expected return of -0.12%. Please make sure to verify Lucid Diagnostics' skewness, day typical price, and the relationship between the maximum drawdown and daily balance of power , to decide if Lucid Diagnostics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Lucid Diagnostics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest inconsistent performance, the Stock's fundamental indicators remain sound and the latest tumult on Wall Street may also be a sign of longer-term gains for the firm shareholders. ...more
1 | Lucid Diagnostics Holds Inaugural CheckYourFoodTube Precancer Testing Event for Former NFL Players | 10/01/2024 |
2 | CVRx Reports Q3 Loss, Tops Revenue Estimates | 10/29/2024 |
3 | Lucid Diagnostics ESOGUARD BE-1 Prospective Multicenter Clinical Validation Study of EsoGuard Esophageal Precancer Testing Accepted for Peer-Reviewed Publicatio... | 11/07/2024 |
4 | Neuronetics Reports Q3 Loss, Lags Revenue Estimates | 11/12/2024 |
5 | Needham maintains Buy rating on Lucid Diagnostics shares | 11/13/2024 |
6 | Lucid Diagnostics Earns Buy Rating from Canaccord Genuity Group | 11/14/2024 |
7 | Lucid Diagnostics Inc. announced that it expects to receive 21.75 million in funding - Marketscreener.com | 11/19/2024 |
8 | Lucid Diagnostics Strategic Financial Maneuvering and Agreements - Nasdaq | 11/29/2024 |
9 | Tesla To 370 Here Are 10 Top Analyst Forecasts For Monday | 12/09/2024 |
10 | Disposition of tradable shares by Sokolov Jacque J of Lucid Diagnostics subject to Rule 16b-3 | 12/10/2024 |
| Begin Period Cash Flow | 22.5 M | |
| Free Cash Flow | -33 M |
Lucid |
Lucid Diagnostics Relative Risk vs. Return Landscape
If you would invest 86.00 in Lucid Diagnostics on September 17, 2024 and sell it today you would lose (8.87) from holding Lucid Diagnostics or give up 10.31% of portfolio value over 90 days. Lucid Diagnostics is currently does not generate positive expected returns and assumes 3.0509% risk (volatility on return distribution) over the 90 days horizon. In different words, 27% of stocks are less volatile than Lucid, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Lucid Diagnostics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Lucid Diagnostics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Lucid Diagnostics, and traders can use it to determine the average amount a Lucid Diagnostics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0398
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | LUCD |
Estimated Market Risk
| 3.05 actual daily | 27 73% of assets are more volatile |
Expected Return
| -0.12 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.04 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Lucid Diagnostics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Lucid Diagnostics by adding Lucid Diagnostics to a well-diversified portfolio.
Lucid Diagnostics Fundamentals Growth
Lucid Stock prices reflect investors' perceptions of the future prospects and financial health of Lucid Diagnostics, and Lucid Diagnostics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Lucid Stock performance.
| Return On Equity | -10.08 | ||||
| Return On Asset | -1.01 | ||||
| Operating Margin | (9.98) % | ||||
| Current Valuation | 101.1 M | ||||
| Shares Outstanding | 59.34 M | ||||
| Price To Book | 2.16 X | ||||
| Price To Sales | 11.13 X | ||||
| Revenue | 2.43 M | ||||
| Gross Profit | (3.24 M) | ||||
| EBITDA | (49.75 M) | ||||
| Net Income | (52.67 M) | ||||
| Cash And Equivalents | 34.46 M | ||||
| Cash Per Share | 0.89 X | ||||
| Total Debt | 15.26 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 4.55 X | ||||
| Book Value Per Share | (0.96) X | ||||
| Cash Flow From Operations | (32.82 M) | ||||
| Earnings Per Share | (1.12) X | ||||
| Market Capitalization | 46.61 M | ||||
| Total Asset | 27.27 M | ||||
| Retained Earnings | (150.74 M) | ||||
| Working Capital | (7.31 M) | ||||
About Lucid Diagnostics Performance
By analyzing Lucid Diagnostics' fundamental ratios, stakeholders can gain valuable insights into Lucid Diagnostics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Lucid Diagnostics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Lucid Diagnostics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 16.97 | 16.12 | |
| Return On Tangible Assets | (2.04) | (2.14) | |
| Return On Capital Employed | 22.96 | 24.10 | |
| Return On Assets | (1.93) | (2.03) | |
| Return On Equity | 22.79 | 23.93 |
Things to note about Lucid Diagnostics performance evaluation
Checking the ongoing alerts about Lucid Diagnostics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Lucid Diagnostics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Lucid Diagnostics generated a negative expected return over the last 90 days | |
| Lucid Diagnostics has some characteristics of a very speculative penny stock | |
| Lucid Diagnostics has high historical volatility and very poor performance | |
| Lucid Diagnostics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 2.43 M. Net Loss for the year was (52.67 M) with loss before overhead, payroll, taxes, and interest of (3.24 M). | |
| Lucid Diagnostics currently holds about 34.46 M in cash with (32.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.89, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Lucid Diagnostics has a poor financial position based on the latest SEC disclosures | |
| Roughly 61.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from benzinga.com: Tesla To 370 Here Are 10 Top Analyst Forecasts For Monday |
- Analyzing Lucid Diagnostics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Lucid Diagnostics' stock is overvalued or undervalued compared to its peers.
- Examining Lucid Diagnostics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Lucid Diagnostics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Lucid Diagnostics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Lucid Diagnostics' stock. These opinions can provide insight into Lucid Diagnostics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Lucid Stock analysis
When running Lucid Diagnostics' price analysis, check to measure Lucid Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lucid Diagnostics is operating at the current time. Most of Lucid Diagnostics' value examination focuses on studying past and present price action to predict the probability of Lucid Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lucid Diagnostics' price. Additionally, you may evaluate how the addition of Lucid Diagnostics to your portfolios can decrease your overall portfolio volatility.
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |